The Beneficial Effects of Actinomycetales Immune Modulators in the Pancreas of Diabetic Rats

Monireh Khordadmehr1, Solin Ghaderi1, Mehran Mesgari-Abbasi2, Farinaz Jigari-Asl1, Katayoon Nofouzi1, Hossein Tayefi-Nasrabadi1, Graham McIntyre4

1Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
2Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran.
4Center for Infectious Diseases and International Health, Windeyeter Institute for Medical Sciences, University College London, UK.

Abstract

Purpose: Type 1 diabetes mellitus (T1DM) has dramatically increased in recent years, especially in young people, and limits the life quality of the patients involved. Thus, many researchers are performing extensive studies to find alternative treatments for DM.

Methods: Here, we evaluated the improvement effects of the heat-killed Actinomycetales species, including Gordonia bronchialis, and Tsukamurella inchonensis in streptozotocin (STZ)-diabetic rats by biochemical, immunological, and histopathological examinations.

Results: The present findings exhibited a dramatic and progressive alteration in the serum levels of interleukin-6 (IL-6), IL-10 and tumor necrosis factor-α (TNF-α) in the diabetic group, which were related to the blood glucose and insulin levels, oxidative stress defense (evaluated by TAC and MDA activities), and the pancreas biochemical indicators (such as amylase and lipase). More importantly, the present results were consistent with the histopathological findings, which included cellular degeneration, vascular congestion, hemorrhage, focal necrosis associated with mononuclear cell infiltration. Interestingly, all of the diabetic changes in the blood serum and tissues improved remarkably in the treated groups by Actinomycetales species.

Conclusion: Surprisingly, most of the current diabetic complications effectively attenuated after oral administration of both Actinomycetales species, particularly with a high dose of T. inchonensis. Thus, it is concluded that the heat-killed Actinomycetales species can prevent and improve the progression of T1DM and its various complications profoundly.

Introduction

Type 1 diabetes mellitus (T1DM) is considered as a multifactorial autoimmune disease in which the islet cell immune response destroys insulin-producing β cells in the endocrine islets of Langerhans. The incidence of T1DM has significantly increased in recent years, particularly among young people, which can affect the patient's life quality. Today, it is well known the contribution of immune-mediated inflammatory mechanisms in the pathophysiology of DM and its complications such as nephropathy and hepatopathy. In this regard, increasing evidence indicated that inflammatory cytokines present a pivotal role in the initiation and progression of T1DM. Recently, some reports described some aerobic Actinomycetales species closely related to mycobacteria including Rhodococcus coprophilous, Gordonia bronchialis, and Tsukamurella inchonensis which are noticeable because of immunomodulatory activities, particularly in heat-killed form. Growing evidence suggested that both obesity and T2DM can be improved by administration of Actinomycetales as an immune modulator. Up to now, there are no data on the effects of these immune modulators on the pancreatic islets alterations associated with biochemical indicators and inflammatory cytokine profiling in the setting of T1DM. A previous document clarified the critical role of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in diabetic complications. Thus, the current study evaluated the probable improvement impact of G. bronchialis and T. inchonensis (as the heat-killed Actinomycetales species) on an improvement to pancreatic islet cell disorders in T1DM through histopathological, immunological and biochemical studies.

Materials and Methods

Experimental design

Sixty healthy adult male Wistar rats weighing approximately 245–365 g, were purchased and divided randomly into six groups (Table 1). T1DM was induced by an intraperitoneal (i.p) injection of streptozotocin...
(STZ) (Sigma-Aldrich Co., USA) with 55 mg/kg dosage in five groups. Blood glucose levels were tested three days later (the animals with the blood glucose greater than 250 mg/dL were considered diabetic), the time-point when treatments were initiated. The treatments were conducted according to Table 1 by two different doses (low dose and high dose) of two the heat-killed Actinomycetales species including G. bronchialis (Gb) and T. inchonensis (Ti) (BioEos Ltd, Kent, UK), and also normal saline (for the diabetic and healthy control groups), which carried out orally for 14 days (consecutively) via stomach gavage needle. The animals were visited every day of the week for 21 days. Blood specimens were obtained after anesthesia (by i.p administration of 50 and 8 mg/kg BW of ketamine and xylazine, respectively) on the 7th, 14th, and 21st days and sera were discreet at 750 × g for 15 min for subsequent biochemical and immunological tests. Besides, five rats in each group were euthanized, and tissue specimens from the pancreas were collected for histopathological evaluation, which placed and fixed at 10% buffered formalin.

Biochemical assays
Serum biochemical indicators evaluation
All of the examined biochemical indicators, including blood glucose levels and serum insulin values, and the activity of amylase and lipase enzymes were measured on the 7th, 14th and 21st sampling days by available commercial kits according to the manufacture’s instructions (Pars Azmoon, Tehran, Iran) and using a spectrophotometer (Photometer 5010, Berlin, Germany).

Serum antioxidant system evaluation
The assays for total antioxidant (TAC) activity and MDA (malondialdehyde) levels were also performed in the obtained sera on the 7th, 14th, and 21st sampling days using the commercial kits according to the manufacture’s protocol (Pars Azmoon, Tehran, Iran) by a spectrophotometer at 593 and 532 nm, respectively.  

TNF-α, IL-6, IL-10 measurement
The levels of IL-6, IL-10, and TNF-α were measured in the stored serum samples on the 14th and 21st sampling days using Rat ELISA commercial kits (Koma Biotech, Korea) according to manufacturer’s instructions.  

Histopathological examination
The formalin-fixed tissue samples were processed routinely, sectioned, stained firstly with hematoxylin and eosin (H&E), and then Gomori’s Aldehyde Fuchsin method was performed, which finally studied microscopically using a light microscope. The tissue sections were examined for the presence of the pathological changes, including atrophy, necrosis, hemorrhage, and vascular congestion. Moreover, insular area (IA) was evaluated in the pancreas sections according to the following formula that presented by the Committee on Care and Use of Laboratory Animal Resources:

\[
AI = \frac{\sum \text{of small islets} \times \text{large islets}}{\sum \text{of observed fields} \times 100 \text{magnification}}
\]

Besides, the numbers of β and α cells were counted in tissue sections stained with Gomori’s Aldehyde Fuchsin method, and the portion of β cells to α cells (β/α cells) was recorded.

Statistical analysis
The present data were analyzed using SPSS software (SPSS, version 16 for windows, USA). As more details, the ANOVA and non-parametric tests were used for statistical analysis of serum parameters and pathological lesions among the various groups, respectively, and a P < 0.05 were considered significant.

Results
The amylose and lipase levels were significantly improved in the diabetic-treated groups
Lower serum insulin levels associated with higher glucose values were identified in the diabetic-control rats compared to the other treated groups. Interestingly, the higher levels of insulin to gather with the lower levels of glucose were observed in the treated groups by using both bacteria, especially in the Ti-recipient group, with dose dependent-manner (data not shown).

The lower activities of amylose, along with higher levels of lipase (Figure 1a, b), were found in the diabetic rats, which were significantly increased in the diabetic-treated groups. Surprisingly, there was a dose-dependent pattern for amylose alteration.

The heat-killed bacteria can improve the serum oxidative stress indicators
The malondialdehyde (MDA) levels (particularly with high-dose of Ti) and TAC activities (particularly with a high-dose of Gb) (Figure 1c, d) significantly differed in the diabetic group rather than the diabetic-treated groups.

Inflammatory cytokines findings were significantly improved in the heat-killed bacteria recipient groups
As expected, we found the notable higher levels of IL-6 and TNF-α pro-inflammatory cytokines together with the markedly lower levels of IL-10 anti-inflammatory
cytokines in the diabetic rats as compared to healthy animals, which improved in all diabetic-treated groups (Figure 2a, b). Among these, IL-10 values did not differ between the low dose and high dose groups. By contrast, the values of TNF-α and IL-6 presented significant differences in a dose-dependent manner.

**Histopathological lesions remarkably reduced in the heat-killed bacteria recipient groups**

Microscopic examination of the pancreas (Figure 3) in the healthy rats demonstrated well-defined acini structures with normal islets of Langerhans. The diabetic animals exhibited degenerative and necrotic changes in both exocrine and endocrine parts, such as the notable disruption and atrophy of Langerhans islets associated with vacuolar degeneration and vascular congestion. Surprisingly, we found strongly significant improvements in the pancreatic structure which clarified by quantitative microscopic evaluation (Table 2), particularly in the size of Langerhans islets (Insular Area) together with β-cells/α-cells (which identified by Gomori’s Aldehyde Fuchsin stain in Figure 4), and at the high dose of Ti in 21 days after treatment which showed nearly normal microscopic morphology. Indeed, there was a progressive degeneration and atrophy of islets in the diabetic control rats from day 14 to 21. In contrast, it was found an incremental improvement in the islets of Langerhans associated with β-cells/α-cells in the treated groups.

**Discussion**

The present findings exhibited the dramatic and progressive alterations in the serum levels of IL-6, IL-10 and TNF-α in the diabetic group, which were related to the blood glucose and insulin levels, oxidative stress defense (evaluated by TAC and MDA activities), the pancreas biochemical indicators (studied by amylase and lipase). More importantly, these data are in agreement with the present histopathological findings, which included severe pancreatic islet destruction. Accordingly, our results are consistent with other observations in the diabetic animal models.3,9 Surprisingly, most of the current diabetic complications induced by STZ were significantly attenuated after oral administration of both *Actinomycetales* species, particularly with a high dose of *T. inchonensis*.

It has been believed that STZ-induced diabetes mellitus and insulin deficiency lead to raised blood glucose and the relation between specific diabetic complications and disturbances in several tissues.10 Here, the serum concentrations of glucose and insulin improved with both treatments of Ti and Gb. Similarly, the present observations are constantly with those of some researchers who investigated the noticeable reduction in serum glucose and insulin levels by the same treatment in experimental T2DM
and obesity in rats, particularly in the Ti-recipient group. It was proposed that both obesity and T2DM associated with some major biochemical indicators and kidney-liver tissue damage, can be improved by the administration of Actinomycetales as an immune modulator. In this regard, it seems that interactions of inflammatory mediators involved in DM, the population of inflammatory cells and defense antioxidant system may play an important role in the improvement of pathological lesions.

Growing evidence demonstrated that the pancreatic exocrine activity is affected by the pancreatic endocrine hormones, particularly insulin, which has a trophic impact on the exocrine cells. Another previous study presented the effect of hyperglycemia on the pancreatic exocrine functions, which significantly modulated with the regulation of glycemic control. Overall, it was believed that in diabetes mellitus, hyperglycemia, and insulin disorders might lead to the pancreatic exocrine dysfunction and the progression of pancreatic exocrine inadequacy. Our results revealed the severe progressive destruction of pancreas structures (mainly islets of the pancreas) by STZ administration in the animals.

More importantly, treatment with both Actinomycetales species, particularly high dose of T. inchonensis, significantly reversed the pancreas structure associated with endocrine (mainly insulin) and exocrine (amylase and lipase) secretions. Convincing evidence postulated that islet (endocrine) hormones could manage pancreatic exocrine activity. Many studies on STZ-induced diabetes in the animals have indicated a decrement in pancreatic enzyme levels, which were attributed to the insulin reduction caused by β-cell damage, which was reversible upon insulin administration. After injection of STZ, pancreatic exocrine secretion alters, so that, on the 7th day, the higher serum level of lipase along with the lower level of amylase was found. Previous reports published alteration of serum pancreatic amylase and lipase enzymes in patients with T1DM and T2DM. In our experiment, the serum levels of amylase and lipase in the treated groups dramatically modulated compared to the diabetic control group, which is in agreement with the previous studies. In summary, it seems that Actinomycetales species can have an improvement effect for attenuation of side effects in various diabetes complications.

It is clarified that oxidative stress represents a critical function in the pathogenesis and development of DM, as well as its related complications. In the present study, TAC activity and MDA levels decreased and increased, respectively, in the diabetic rats with no treatment, which changed effectively by oral administration of both T. inchonensis and G. bronchialis, particularly in a dose-dependent manner. Indeed, oxidative stress develops in DM through enhanced production of reactive oxygen species, which attribute to excessive lipid peroxidation due to the lipid degradation. Subsequently, it can lead

| Groups     | No. small islets (P value=0.12) | No. large islets (P value=0.05) | Insular Area (P value=0.01) | β-cells/α-cells (P value=0) |
|------------|---------------------------------|---------------------------------|-----------------------------|----------------------------|
| HC         | 1.31±0.39                       | 2.14±0.69                       | 30.29±9.85                  | 3.47±0.24                  |
| DC         | 0.32±0.11                       | 0.28±0.14                       | 10.32±3.19                  | 1.12±0.28                  |
| T1         | 0.54±0.19                       | 0.51±0.15                       | 17.26±8.43                  | 2.24±0.16                  |
| T2         | 0.94±0.16                       | 1.86±0.39                       | 28.47±9.38                  | 3.17±0.14                  |
| G1         | 0.62±0.21                       | 0.49±0.17                       | 14.22±5.94                  | 1.96±0.25                  |
| G2         | 0.81±0.17                       | 1.07±0.28                       | 21.49±7.36                  | 2.52±0.23                  |

HC: healthy control; DC: diabetic control; T1: diabetic rat treated with the low dose of Ti (10⁵ CFU/rat); T2: diabetic rat treated with the high dose of Ti (10⁶ CFU/rat); G1: diabetic rat treated with the low dose of Gb (10⁵ CFU/rat); G2: diabetic rat treated with the high dose of Gb (10⁶ CFU/rat).

Figure 2. The effects of oral administration of Actinomycetales species on the serum levels of IL-6, IL-10, and TNF-α on the 14th (a) and 21st (b) sampling days on STZ-induced diabetes. Data are presented as the mean ± SD. Differences were considered significant with P < 0.05. a: A significant difference with healthy control (HC); b: A significant difference with diabetic control (DC); *: A considerable difference between low dose and high dose treated groups.
The beneficial effects of Actinomycetales in T1DM
Advanced Pharmaceutical Bulletin, 2021, Volume 11, Issue 2

...to harmful effects via the accumulation of free radicals, which impairs cell membrane function, leading to the tissue damage.\textsuperscript{17}

Here, we observed a marked alteration of the major pro- and anti-inflammatory cytokines involved in diabetes pathogenesis, including IL-10, IL-6, and TNF-α in the diabetic rats, which significantly attenuated after treatment by heat-killed Actinomycetales species. As more details, our findings exhibited that alterations of IL-6 and TNF-α were more dose and time-dependent than IL-10. What’s more, it seems that a high dose of Ti can severely manage serum cytokine profile in DM. The inflammatory cytokines originated from peripheral blood T cells, or macrophages provide a crucial role in the induction
and progression of diabetes.\textsuperscript{18} Recently, it was proposed that circulating cytokines in DM links with inhibiting the cytotoxicity in pancreas β-cells.\textsuperscript{19} A previous study exhibited that hyperglycemia accelerates the development of the chronic inflammatory processes in patients with DM.\textsuperscript{20} Accordingly, high levels of glucose promotes IL-6 secretion, which can be described that persistent hyperglycemia provides the formation of advanced glycation end-products.\textsuperscript{21} Additionally, IL-6 modulates insulin secretion. Indeed, low content of IL-6 can promote insulin production, while its high concentration inhibits insulin secretion.\textsuperscript{22}

TNF-α is responsible for the progression of T1DM and T2DM through the prevention of glucose-induced insulin secretion and the destruction of β-cell function and inducing apoptosis.\textsuperscript{23} It was pointed that abnormal conditions like hyperglycemia and enhanced oxidative stress can stimulate the activation of the protein complex of the JNK (c-Jun N-terminal kinase) pathway and the NF-κB (nuclear factor Kapa B) signaling, which can release the pro-inflammatory mediators such as IL-6 and TNF-α.\textsuperscript{24,25}

It is demonstrated that anti-inflammatory cytokines such as IL-10 (secreted from Th2 cells) exhibited a protective impact against diabetes progression in the animal model.\textsuperscript{26} It was proposed that IL-10 decreased in T2DM, which is associated with risk of DM.\textsuperscript{27,28} In this regard, it is established that it can modulate or inhibit the production of TNF-α and IL-6.\textsuperscript{29} It was also mentioned that the high IL-10 concentrations inhibit the progression of T2DM and its metabolic syndrome by reducing the results of the inflammatory response such as TNF-α and IL-6.\textsuperscript{30}

Conclusion

In conclusion, the present findings indicated that heat-killed Actinomycetales species could protect the pancreas functions efficiently in T1DM, which was evidenced by the biochemical indicators, inflammatory cytokine profiles, and the histopathological examination. Overall, it was concluded that oral administration of heat-killed Actinomycetes species in the diabetic rats could provide them a potentially strong candidate for industrial application as pharmacological agents for the treatment of some diabetic dysfunctions.

Ethical Issues

The experiment was authorized by the Research Ethics Committee, Tabriz University of Medical Sciences, Iran (ethical approval code: 5-4-1171, date: 4 May 2013).

Conflict of Interest

There is no conflict of interest.

Acknowledgments

The authors express their gratitude to Professor Graham McIntyre, of BioEos Ltd. for the preparation and provision of heat-killed Actinomycetales species. This work was supported by the Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran, and also the Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

References

1. Patterson C, Guargiuata L, Dahlquist G, Soltész G, Ogle G, Silink M. Diabetes in the young-a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract 2014;103(2):161-75. doi: 10.1016/j.diabres.2013.11.005
2. Stanford J, Stanford C. Mycobacteria and their world. Int J Mycobacteriol 2012;1(1):3-12. doi: 10.1016/j.ijmyco.2012.01.001
3. Tarrés MC, Gayol Mdel C, Picena JC, Alet N, Bottasso O, McIntyre G, et al. Beneficial effects of immunotherapy with extracts derived from Actinomycetales on rats with spontaneous obesity and diabetes. Immunotherapy 2012;4(5):487-97. doi: 10.2217/int.12.37
4. Mohamed J, Nazratan Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J 2016;16(2):e132-41. doi: 10.18295/squmj.2016.16.02.002
5. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19(3):433-42. doi: 10.1681/asn.2007091048
6. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: Saunders; 1999.
7. Ausubel M, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al. Current Protocols in Molecular Biology. Vol 1. Hoboken, NJ: John Wiley & Sons Inc; 2003.
8. Hassanaliou T, Payahoo L, Shahabi P, Mesgari Abbasi M, Asghari Jafar-abadi M, Khaje Bishak Y, et al. The protective effects of Morus nigra L. leaves on the kidney function tests and histological structures in streptozotocin-induced diabetic rats. Biomed Res Int 2017;28(14):6113-8.
9. Zafar M, Naqi SN, Ahmed M, Kaimkhani ZA. Altered liver morphology and enzymes in streptozotocin induced diabetic rats. Int J Morphol 2009;27(3):719-25. doi: 10.4067/ s0717-95022009000300015
10. Saeed MK, Deng Y, Dai R. Attenuation of biochemical parameters in streptozotocin-induced diabetic rats by oral administration of extracts and fractions of Cephalotaxus sinensis. J Clin Biochem Nutr 2008;42(1):21-8. doi: 10.3164/jcbn2008004
11. Barreto SG, Carati CJ, Tossi J,Saccone GT. The islet-acinar axis of the pancreas: more than just insulin. Am J Physiol Gastrointest Liver Physiol 2010;299(1-G10:22. doi: 10.1152/ajpgi.00077.2010
12. Ata N, Dal K, Kucukazman M, Yeniava G, Karakaya S, Unsal O, et al. The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels. Open Med (Wars) 2015;10(1):8-13. doi: 10.1515/med-2015-0002
13. Nakajima K, Oshida H, Munezuki T, Kakei M. Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency. Core Evid 2012;7:77-91. doi: 10.2147/ce.s26705
14. Augheesten AA, Mohammed FI. Insulin enhances amylase
and lipase activity in the pancreas of streptozotocin-diabetic rats. An in vivo study. *Saudi Med J* 2002;23(7):838-44.

15. Augheetna AA, Abu-Umair MS, Mahmoud SA. Biochemical analysis of serum pancreatic amylase and lipase enzymes in patients with type 1 and type 2 diabetes mellitus. *Saudi Med J* 2005;26(1):73-7.

16. Tanvi NEJ, Akhter QS, Nahar S, Sumi MN, Hosen M. Serum amylase and lipase levels in type 2 diabetes mellitus. Journal of Bangladesh Society of Physiologist 2017;12(2):52-56. doi: 10.3329/jbsp.v12i2.35422

17. Hanachi P, Heydari Moghadam R, Abdul Latiff L. Investigation of lipid profiles and lipid peroxidation in patients with type 2 diabetes. *Eur J Sci Res* 2009;28(1):6-13.

18. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: a novel cellular receptor for advanced glycation end products. *Diabetes* 1996;45 Suppl 3:S77-80. doi: 10.2337/diab.45.3.s77

19. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. *Adv Exp Med Biol* 2016;893:1-19. doi: 10.1007/978-3-319-24223-1_1

20. Fisman EZ, Tzenbaum A. The ubiquitous interleukin-6: a time for reappraisal. *Cardiovasc Diabetol* 2010;9:62. doi: 10.1186/1475-2840-9-62

21. Nevado J, Peiró C, Vallejo S, El-Assar M, Lafuente N, Mateansz N, et al. Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. *Br J Pharmacol* 2005;146(2):268-79. doi: 10.1038/sj.bp.7006309

22. Wedrychowicz A, Dziatkowiak H, Sztelko K, Wedrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. *Exp Clin Endocrinol Diabetes* 2004;112(8):435-9. doi: 10.1055/s-2004-821189

23. Seven A, Guezel S, Seymen O, Civelek S, Bolayirli M, Uncu M, et al. Effects of vitamin E supplementation on oxidative stress in streptozotocin induced diabetic rats: investigation of liver and plasma. *Yonsei Med J* 2004;45(4):703-10. doi: 10.3349/ymj.2004.45.4.703

24. Manna P, Das J, Ghosh J, Sil PC. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: prophylactic role of arjunolic acid. *Free Radic Biol Med* 2010;48(11):1465-84. doi: 10.1016/j.freeradbiomed.2010.02.025

25. Martínez-Flórez S, Gutiérrez-Fernández B, Sánchez-Campos S, González-Gallego J, Tuñón MI. Quercetin attenuates nuclear factor-kappaB activation and nitric oxide production in interleukin-1beta-activated rat hepatocytes. *J Nutr* 2005;135(6):1359-65. doi: 10.1093/jn/135.6.1359

26. Papaccio G, Pisanti FA, Montefiano RD, Graziano A, Latronico MV. Th1 and Th2 cytokines exert regulatory effects upon islet microvascular areas in the NOD mouse. *J Cell Biochem* 2002;86(4):651-64. doi: 10.1002/jcb.10250

27. Yaghini N, Mahmoodi M, Asadikaram GR, Hassanshahi GH, Khoramdelazad H, Kazemi Arababadi M. Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes. *Iran Red Crescent Med J* 2011;13(10):752.

28. Hua Y, Shen J, Song Y, Xing Y, Ye X. Interleukin-10 -592C/A, -819C/T and -1082A/G polymorphisms with risk of type 2 diabetes mellitus: a HuGE review and meta-analysis. *PLoS One* 2013;8(6):e66568. doi: 10.1371/journal.pone.0066568

29. Carey AJ, Tan CK, Ulett GC. Infection-induced IL-10 and JAK-STAT: a review of the molecular circuitry controlling immune hyperactivity in response to pathogenic microbes. *Jkstat* 2012;1(3):159-67. doi: 10.4161/jkst.19918

30. van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma Van Der Wiel A, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. *Diabetes* 2002;51(4):1088-92. doi: 10.2337/diabetes.51.4.1088